Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 4/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | PRKCI | P41743 | 1/20 | 0.30 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
| ▸ | LPL | P06858 | 1/20 | 0.30 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16008825 | 0.84 | FFAR1 (0.40) | FFAR1LPLLIPG | |
| SCHEMBL30523101 | 0.84 | FFAR1 (0.40) | FFAR1LPLLIPG | |
| SCHEMBL19891733 | 0.75 | LMNA (0.30) | LMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL22185786 | 0.73 | LPL (0.40) | FFAR1LPLLIPG | |
| SCHEMBL21201415 | 0.73 | LPL (0.37) | FFAR1LPLLIPG | |
| SCHEMBL23597018 | 0.72 | FFAR1 (0.44) | FFAR1LPLLIPG | |
| SCHEMBL22289520 | 0.72 | FFAR1 (0.42) | FFAR1LPLLIPG | |
| SCHEMBL29506948 | 0.70 | AR (0.40) | FFAR1LPLLIPG | |
| SCHEMBL406138 | 0.70 | AR (0.40) | FFAR1LPLLIPG | |
| SCHEMBL22977685 | 0.70 | DGAT1 (0.38) | FFAR1LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10189826-B2 | Heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2019-01-29 | — | — | US | disclosed |
| US-20180051013-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2018-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189826-B2 | Heterocyclic compounds and methods of use | HRAS, VHL, ESRRB | ALDH1A1 2384/4885LMNA 2671/4885SMN1; SMN2 4036/4885 |
| US-20180051013-A1 | Heterocyclic Compounds and Methods of Use | HRAS, VHL, ESRRB | ALDH1A1 2384/4885LMNA 2671/4885SMN1; SMN2 4036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.